STAT

Opinion: Ending tuberculosis: we can get there with a new roadmap

The Lancet Commission has set an audacious goal of achieving a world that's free of #TB within a generation. We will need new tools and strategies to get there. #WorldTBDay
Scientists work in the tuberculosis research laboratory of the Pasteur Institute in 1938. The only licensed TB vaccine today, the Bacille Calmette-Guerin vaccine, was developed 17 years earlier.

Two recent events have nudged tuberculosis, the leading infectious cause of death around the word, onto the world stage. The first was the World Health Organization’s Global Ministerial Conference on Ending TB, which was held in Moscow in 2017. The second was the United Nations High Level Meeting on tuberculosis in September 2018. At that seminal gathering of national leaders, a political declaration laid out two goals to achieve by 2022: prevent at least 30 million people from becoming ill with TB, and successfully treating 40 million people who are already infected with the disease.

That’s an audacious goal, especially given the fact that most of the tools currently available to prevent,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks